Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAS(ON) Inhibitors + Ivonescimab in Advanced Solid Tumors
NCT07397338Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- Jan 2026
- Primary completion
- May 2029
- Modality
- Antibody Conjugates, Cyclic Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daraxonrasib, elironrasib, zoldonrasib, ivonescimab in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Revolution Medicines. Started Jan 2026; status: recruiting.
02
Drugs
daraxonrasibelironrasibzoldonrasibivonescimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07397338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07397338.